To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The leader of the Triad’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Adam Schechter successfully led ...

The following is a transcript of an interview with LabCorp CEO Adam Schechter that aired Sunday, October 4, 2020, on "Face the Nation." MARGARET BRENNAN: LabCorp was the first commercial lab to offer ...

The pandemic provided an unprecedented growth opportunity in diagnostic testing. COVID-19 tests took off, first, at testing sites — and later at home, Labcorp (LH) CEO Adam Schechter told Yahoo ...

Labcorp CEO Adam Schechter said on Closing Bell that vaccine recipients are not being advised to be tested for COVID-19 antibodies after immunization, reported CNBC. There have been questions about ...

LabCorp CEO Adam Schechter told CNBC July 21 that the spread of COVID-19 in the U.S. is too fast for the company to keep up with demand, causing slower turnaround times for test results. The ...

BURLINGTON — LabCorp on Tuesday reported a first-quarter profit of $212.9 million – not quite meeting Wall Street expectations. But revenues did collectively beat the target of analysts. The numbers ...

BURLINGTON – Labcorp on Thursday reported a third-quarter profit of $352.8 million yet its overall financials didn’t meet Wall Street expectations. But CEO Adam Schechter said the company “made ...

Reports Q3 revenue $3.28B, consensus $3.26B. “Labcorp (LH) achieved strong performance in Diagnostics and Biopharma Laboratories, including robust organic growth in the third quarter,” said Adam ...

Adam Schechter, chairman and CEO of coronavirus testing giant LabCorp, thinks it's highly unlikely that corporate workplaces will ever return to normal, or to way they were before the pandemic.

The yet-to-be-named new company will be publicly traded. Separating the laboratory testing work of LabCorp from the clinical trial services business, much of which came from acquisitions, will enable ...